Document is current

Article History

Received: 5 June 2023

Accepted: 27 June 2023

First Online: 13 July 2023

Declarations

:

: The study had ethical approval and STROBE guidelines were followed.

: Not applicable.

: The authors declare the following financial interests or personal relationships that may be considered competing interests: KB and LMW have no conflicts of interest. FR received personal fees from Angelini Pharma/Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals/Jazz Pharma, Roche Pharma, and UCB Pharma, and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF), the LOEWE Programme of the State of Hesse, and the European Union. FR reports, that he is a part of the editorial board of Neurological Research and Practice. SK received personal fees and grants from Angelini Pharma, Bial, Desitin Arzneimittel, Epilog, Kanso, UCB Pharma, UNEEG, and Zogenix. LK received speaker honoraria from UCB, Merck and Eisai, congress/travel support from UCB and Angelini Pharma, and personal grants from the Michael Foundation, Finnish neurology association, and HUS Neurocenter. AS received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz (GW) Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB (Zogenix) Pharma, and UNEEG medical. AS reports, that he is a part of the editorial board of Neurological Research and Practice.